11 am – 12:15 pm
Break-through products such as biologics and specialty drugs promise extended lives or first-ever cures for individuals. Yet some price tags in this $310 billion U.S. market have shocked those who foot the bill—including state governments, Medicaid, employers, health insurers and patients themselves. States are considering a variety of legislation to rein in costs, assist consumers or shift the burden. Terms such as "medically necessary," "medication adherence," "fail first," "preferred drug lists," "value-based purchasing" and "interchangeable biosimilar substitution" make state capitals sound like pharmacies. Hear state and medical experts sort out the headlines, the noise and the results so far.
With advances in modern medicine, Americans face more options regarding the care they receive at the end of life. In this lunch session, hear about a range of topics related to end-of-life decisions and empowering individuals.